---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014396"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:49:26.085441+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Virios Q2 net loss $1.4M ($0.08/share); cash $4.6M; FDA IMC-1 toxicology adequate; pK study planned

## Summary
- Net loss $1.4M ($0.08 per share) vs $3.7M ($0.44) in Q2 2022; R&D down to $0.6M, G&A down to $0.9M.
- Cash $4.6M at June 30, plus $1.4M raised via July Sales Agreement; runway at least 12 months.
- FDA indicates IMC-1 chronic toxicology program adequate to support Phase 3 fibromyalgia study.
- Pk/food-effect study planned for H2 2023; first Phase 3 FM study enrollment targeted for mid-2024.
- IMC-2 Long-COVID: new double-blind placebo-controlled study with Bateman Horne Center; FDA meeting to discuss Phase 2.

## SEC filing metadata
- accession: 0001558370-23-014396
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/0001558370-23-014396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/tmb-20230810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014396
- JSON: https://secwatch.observer/filing/0001558370-23-014396.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014396.txt

## Key facts
- Earnings Releases
  Dogwood Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $1.4 million, EPS $0.08 basic and diluted net loss per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: $1.4 million
  - EPS: $0.08 basic and diluted net loss per share
  - Result: reported results
  source text: Net loss for the second quarter of 2023 was $1.4 million, or $0.08 basic and diluted net loss per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837023014396/0001558370-23-014396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.